Fig. 4.
Kaplan-Meier estimates of median, 2-, 3-, and 4-year overall survival of real-world patients with advanced melanoma with characteristics according to trial eligibility criteria, treated with first-line BRAF-MEK inhibitors.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.